Seagen’s Tukysa (tucatinib) has been approved by the European Commission (EC) as part of a triple-combination therapy for people with previously treated advanced or metastatic HER2-positive breast cancer. The EC approved Tukysa, when given alongside trastuzumab and the chemotherapy medication Xeloda (capecitabine), for patients who have received at least two anti-HER2-based treatments for metastatic disease. With this…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Biond and Sanofi Partner, Plan for Trial of Checkpoint Inhibitor BND-22
Biond Biologics and Sanofi have entered into a worldwide licensing agreement to advance BND-22, a novel immune checkpoint inhibitor, into clinical testing as a potential treatment of solid tumors. An investigational new drug (IND) application, requesting that the treatment be cleared for patient trials, was recently filed with the U.S. Food and Drug Administration. If…
Xpovio Approved in Israel for Some Myeloma, Lymphoma Patients
The Israeli Ministry of Health has approved Xpovio (selinexor), in combination with the corticosteroid dexamethasone, for the treatment of people with multiple myeloma who have received three or more prior therapies, and who failed to respond to at least one immunomodulatory agent, one proteasome inhibitor, and one CD38 inhibitor. Xpovio also has won approval in…
FDA Approves Libtayo, 1st Immunotherapy for Advanced Basal Cell Carcinoma
The U.S. Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc), making it the first immunotherapy for people with advanced basal cell carcinoma (BCC) — the most common form of skin cancer — who previously received or were ineligible for treatment with a hedgehog pathway inhibitor. Based on the results of an ongoing Phase 2…
‘TRUE Love’ Contest Calls for Entries Honoring Caregivers
With help from actress Kristen Bell, the Prostate Cancer Foundation (PCF) has opened its 4th annual TRUE Love contest for entries that pay tribute to family members and caregivers of men living with prostate cancer. The organization is seeking caregiving narratives that show love, care, and honor for prostate cancer patients to raise awareness about…
ENB-003 with Keytruda Shows Promise Against Advanced Solid Tumors
ENB Therapeutics’ lead novel anti-cancer therapy, ENB-003, was found to be safe and showed promising anti-tumor activity, when given in combination with Keytruda (pembrolizumab), to adults with different types of advanced solid malignancies, including ovarian cancer and melanoma. These are the early findings of an open-label Phase 1/2 trial (NCT04205227) that has recently finished dosing…
Trial Testing AL101 in TNBC Doses First Patient
The first participant has been dosed in the Phase 2 clinical trial TENACITY, which is evaluating Ayala Pharmaceuticals‘ investigational therapy AL101 as a treatment for Notch-activated recurrent or metastatic triple negative breast cancer (TNBC). AL101 is an investigational small molecule that inhibits Notch proteins. This family of cellular proteins plays important roles in governing cell…
New AI Tool May Better Predict Relapse After Surgery
Researchers have developed an artificial intelligence (AI) tool that shows the potential to predict prostate cancer aggressiveness and the likelihood of post-surgery relapse more accurately than standard methods can. Called RadClip, for radiomic-clinicopathologic nomogram, the tool was developed by a team from the Center for Computational Imaging and Personalized Diagnostics (CCIPC) at Case Western Reserve…
FDA Clears Way for Clinical Trial of HDP-101
Heidelberg Pharma has been cleared in the U.S. to begin a clinical trial testing its investigational therapy HDP-101 for the treatment of multiple myeloma. The U.S. Food and Drug Administration (FDA) allowed the start of a Phase 1/2a trial following the submission of an investigational new drug (IND) application. The company expects to enroll the…
CAR T-cell Therapy Breyanzi Approved for Large B-cell Lymphomas
The U.S. Food and Drug Administration (FDA) has approved the CAR T-cell therapy Breyanzi (lisocabtagene maraleucel) for treating adults with relapsed or refractory large B-cell lymphoma (LBCL) who have had two or more lines of systemic therapy. The approval covers several types of LBCL: diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising…
€15M EU Project Seeks to Improve Personalized Medicine Options
The European Union is providing nearly €15 million ($18.1 million) over five years to improve personalized medicine options for people with drug-resistant high-grade serous ovarian cancer. The DECIDER project, funded by the EU’s Horizon 2020 research and innovation program, will apply artificial intelligence methods to develop new diagnostic tools to identify — earlier and more…
Under-the-skin Velcade Found to Work Better in Farydak Triple Combo
Using an under-the-skin formulation of Velcade (bortezomib), in combination with Farydak (panobinostat) and oral dexamethasone, leads to a better safety profile in people with relapsed or refractory (resistant) multiple myeloma than does the therapy’s original into-the-vein version, data show. The triple combination treatment with under-the-skin Velcade also was found to induce longer responses than the…